Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

Eric Van Cutsem,Iwona Danielewicz,Mark P Saunders,Per Pfeiffer,Guillem Argiles,Christophe Borg,Rob Glynne-Jones,Cornelis J. A. Punt,Agnes J. van de Wouw,Mikhail Fedyanin,Daniil Stroyakovskiy,Hendrik Kroening,Pilar García-Alfonso,Harpreet Wasan,Alfredo Falcone,Paul Aubel,Anton Egorov,Nadia Amellal,Vladimir Moiseenko

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

2021

Eric Van Cutsem
Iwona Danielewicz
Mark P Saunders
Per Pfeiffer
Guillem Argiles
Christophe Borg
Rob Glynne-Jones
Cornelis J. A. Punt
Agnes J. van de Wouw
Mikhail Fedyanin
Daniil Stroyakovskiy
Hendrik Kroening
Pilar García-Alfonso
Harpreet Wasan
Alfredo Falcone
Paul Aubel
Anton Egorov
Nadia Amellal
Vladimir Moiseenko

14Background: Our phase II randomized study was conducted in patients with previously untreated unresectable mCRC not eligible to receive standard oxaliplatin- or irinotecan- based chemotherapy reg...

Keywords:

Colorectal cancer
Chemotherapy
Oncology
Internal medicine
Bevacizumab
Oxaliplatin
Irinotecan
Capecitabine
Phases of clinical research
Medicine
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations